Clinical trial
Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or…
NCT00352677 · CytRx, Industry · Completed
Key facts
| NCT number | NCT00352677 |
|---|---|
| Title | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia |
| Official title | A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INNO-406 in Adult Patients With Imatinib-Resistant or Intolerant Philadelphia Chromosome-Positive (Ph+) Leukemias |
| Lead sponsor | CytRx, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | INNO-406 |
| Enrollment | 100 |
| Start date | Jul 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jul 17, 2006 |
| Last update posted | Jun 1, 2009 |
| Countries | Germany, Israel, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: